ALPMY - Astellas Mogrify team up to discover regenerative medicines for hearing loss

• Japan's Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) is collaborating with U.K.-based Mogrify to research on in vivo regenerative medicine approaches to address sensorineural hearing loss.
• Under the agreement, the companies will use Mogrify's proprietary direct cellular reprogramming platform to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair cells.
• Astellas Gene Therapies, a division of Astellas, will cover the research cost of the work and provide its expertise in adeno-associated virus (AAV) based genetic medicine to complete experiments in pre-clinical models. Mogrify will use its bioinformatic platform, screening and validation process to characterize potential therapeutic factors, according to a July 5 press release.
• sensorineural hearing loss is caused due to damage to the inner ear or the nerve from the ear to the brain.

For further details see: